News

Caliway Achieves Major Milestones with CBL-514 Study Success

Caliway Achieves Major Milestones with CBL-514 Study Success

CBL-514 Shows Promising Results in Phase 2b Trial

CBL-514, the pioneering investigational drug aimed at large-area localized fat reduction, has achieved significant efficacy benchmarks in its recent Phase 2b trial (CBL-0205). This study, which serves as the final step before entering Phase 3 trials, has produced impressive results that underline the drug's potential as a breakthrough treatment for those seeking fat reduction solutions.

Key Findings from CBL-514 Phase 2b Study

The study featured a cohort of 173 participants afflicted with notable abdominal fat accumulation, assessed through the Abdominal Fat Rating Scale (AFRS). Remarkably, 54.2% of these participants realized at least a 20% reduction in fat volume just four weeks post-treatment. This statistic stands in stark contrast to the placebo group, which demonstrated a 0% reduction.

Furthermore, approximately 75.7% of those treated with CBL-514 recorded at least a 1-grade improvement in their CR-AFRS assessments, showcasing the drug's effectiveness in improving overall fat levels. Participants also reported substantial enhancements as observed from both a medical and personal perspective, with average fat volume reductions reaching above 166 mL within the same four-week timeframe.

Study Design and Methodology

The design of CBL-0205 was thoroughly structured to establish a strong framework for evaluating the drug’s impact. Conducted as a multi-center, double-blind, randomized, and placebo-controlled trial, it ensures high reliability in its findings. Participants were administered injections subcutaneously to their abdominal regions, spaced three weeks apart, allowing ample time for monitoring treatment effects and safety.

Secondary Efficacy Outcomes

In addition to the primary endpoints, secondary efficacy outcomes confirmed the robust performance of CBL-514. MRI data indicated that participants in the CBL-514 group not only excelled in fat volume reduction compared to the placebo group, but also outperformed alternative treatments listed as CBL-A1 and CBL-A2. This is pivotal as it sets the groundwork for CBL-514 being a front-runner in its category.

Next Steps for Caliway Biopharmaceuticals

With the recent accomplishments, Caliway Biopharmaceuticals is poised to commence its global Phase 3 studies. The company plans to recruit about 600 participants across two pivotal trials, slated for the latter half of the upcoming year. This is an exciting chapter as the company aims to redefine standards within the aesthetic medicine market, providing revolutionary solutions to unmet medical needs.

Overview of CBL-514 and the AFRS Scale

CBL-514 is regarded as a groundbreaking small-molecule injectable that targets adipocyte (fat cell) apoptosis, promoting a significant reduction in localized fat deposits without adverse effects on the central nervous, cardiovascular, or respiratory systems. The Abdominal Fat Rating Scale (AFRS), which was devised by Caliway, incorporates both clinician and patient evaluations to gauge treatment efficacy effectively.

About Caliway Biopharmaceuticals

Caliway Biopharmaceuticals is a forward-thinking clinical-stage company committed to innovative drug discovery. As they pursue their mission to lead in aesthetic medicine, their work is underscored by rigorous clinical evaluation and a commitment to unearthing novel therapeutic solutions. This dedication positions Caliway as a promising player on the Taiwan Exchange market (TWSE-6919), and industry stakeholders are keenly watching its advancements.

Frequently Asked Questions

What is CBL-514?

CBL-514 is an injective lipolysis drug designed for large-area localized fat reduction, aiming for significant results without major side effects.

How many participants were involved in the study?

The Phase 2b study included 173 participants with moderate to severe abdominal fat accumulation.

What were the primary outcomes of the Phase 2b trial?

The primary outcome was a minimum of 20% fat volume reduction four weeks after treatment, which was achieved by 54.2% of subjects in the CBL-514 group.

When are the Phase 3 studies expected to begin?

Caliway plans to start these pivotal Phase 3 studies in the second half of 2025, with approximately 600 participants expected to enroll.

What does the Abdominal Fat Rating Scale measure?

The AFRS measures and categorizes abdominal fat accumulation, providing a standard for assessing changes in fat volume and treatment effectiveness.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Huawei's Financial AI Push Targets Scale, Not Demos

Updated Category News Views 79

Banking AI has reached the point where a clever chatbot barely moves the needle. Huawei's message at Singapore FinTech Festival 2026 was aimed squarely at that harder, more expensive problem: turning AI from a scattered pilot project into machinery a financial institution can operate, govern, repeat, and improve without handing over its crown jewels. Ownership Is the...

Continue Reading
VIGGO’s Mix1Pro Tests Practical Commercial Cleaning

Updated Category News Views 53

A cleaning robot earns its keep in the ugly corners, not under convention-center lights. VIGGO used the ISSA Show North America gathering in Las Vegas, held November 17–19, 2026, to introduce the Mix1Pro, a compact commercial machine aimed at indoor facilities below 53,800 square feet. That target matters. Smaller, messier sites are where autonomy can look terrific on a...

Continue Reading
Babe Ruth Lots Lead Morphy's $2 Million Collectibles Auction

Updated Category News Views 44

Ruth still pulls money like few names ever will, and Morphy's November 10-12 auction made that plain without any circus tricks. Three lots tied to the Yankees legend produced $136,500 within a Toys, Sports & General Collectibles sale that topped $2 million. That is not some vague nostalgia story. Buyers put real dollars behind a 1932 U.S. Caramel card, a 1933 Goudey card,...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 25

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
Straub's Court Win Raises Cost of Seven-Year Fight

Updated Category News Views 51

Seven years of courtroom smoke over an under-$80,000 lien is the sort of mess that makes any business owner grind his teeth. Palm Beach Polo says its president, Glenn Straub, has again prevailed against Jessica Nicodemo in Palm Beach County, following an earlier Broward County dismissal of related claims. The company also says Vice President Sal Spano received a directed...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 31

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
PetSmart Charities Adds Strategy Role for Pet Families

Updated Category News Views 464

A pet bowl can become a crisis marker faster than people admit. Housing trouble, empty cupboards, a hurricane, or an unaffordable veterinary bill can turn a loved animal into one more impossible responsibility. That is the uncomfortable reality behind PetSmart Charities' decision to create a vice president of strategic programs and partnerships role and appoint Heather...

Continue Reading
UTI Faces Fresh Scrutiny After Its Earnings Guidance Miss

Updated Category News Views 113

A Guidance Gap That Cannot Be Shrugged Off A $0.20-per-share hole is a nasty thing to find after management said it could see the road ahead. Universal Technical Institute reported fiscal 2026 diluted earnings per share of $0.60, below the $0.71 to $0.80 range it reaffirmed on May 6. That is at least $0.11 under the low end and roughly 21% below the midpoint. For...

Continue Reading
COFE+ Barista Test Puts Robotic Coffee on the Clock

Updated Category News Views 66

A swan latte taking 18 seconds less is not nothing, even if it is hardly a verdict on the future of coffee. COFE+, the seventh-generation robotic barista from Shanghai Hi-Dolphin Robot Technology, beat an award-winning human barista across five drinks at a live November 14 competition in Yiwu. That is a clean, visible demonstration of what machines are increasingly built...

Continue Reading

Top 5 Most Recently Viewed Articles

ProQR Initiates Presentation at Citizens Life Sciences Event

Updated Category News Views 132

ProQR Therapeutics to Present at Citizens Life Sciences Conference ProQR Therapeutics N.V. (Nasdaq: PRQR), dedicated to transforming lives through innovative RNA therapies, has announced a presentation scheduled for the Citizens Life Sciences Conference in New York City. The event will take place on a specified date, and ProQR’s management team is set to delve into...

Continue Reading
Man Group PLC Highlights Positions in American Axle & Manufacturing

Updated Category News Views 113

Understanding Man Group PLC's Position in American Axle & Manufacturing Man Group PLC is making headlines as it reveals significant details regarding its position in American Axle & Manufacturing Holdings, Inc. This disclosure showcases the firm's strategic interests in relevant securities, representing a noteworthy percentage that meets regulatory requirements. Key...

Continue Reading
Ocular Therapeutix Transforms Brand with Focus on Retina Care

Updated Category News Views 296

Ocular Therapeutix Modernizes Brand to Emphasize Retina Health In a significant move aimed at aligning its identity with its mission, Ocular Therapeutix, Inc. (NASDAQ: OCUL) has launched an innovative corporate branding initiative along with a new website. This transition marks a pivotal shift towards a dedicated focus on retinal health, showcasing the company’s...

Continue Reading
Raytron's Innovative OGI Cameras Enhance Ozone Layer Protection

Updated Category News Views 195

Raytron's Commitment to Ozone Layer Preservation As the International Day for the Preservation of the Ozone Layer approaches, global attention focuses on looming threats to atmospheric recovery, particularly from greenhouse gases that continue to pose significant risks. While advancements have been made to eliminate CFCs under the Montreal Protocol, the ongoing rise in...

Continue Reading
Booz Allen Hamilton's CFO Makes Strategic Stock Sale Decision

Updated Category News Views 119

Booz Allen Hamilton Holding Corp. (NYSE: BAH) just served up some intriguing corporate moves with its Executive Vice President and Chief Financial Officer, Matthew Calderone, making headlines. He recently sold off 3,865 shares of the company's Class A Common Stock for a substantial total of $618,400. That kind of action doesn’t happen in a vacuum; it's a signal that...

Continue Reading